Merck’s $6.7B acquisition of Terns Pharmaceuticals highlights huge potential in CML therapies. Why analysts see Enliven’s ELVN-001 as a best-in-class winner with strong takeover appeal.
Merck is buying Terns Pharmaceuticals for $6.7 billion to add TERN-701, a promising new oral drug for chronic myeloid leukemia (CML). The move strengthens its cancer pipeline as Keytruda patent expiry nears in 2028.
Enliven Therapeutics (ELVN) reports encouraging Phase 1b results for ELVN-001, a new treatment for chronic myeloid leukemia, with strong response rates and excellent safety profile.
William Blair upgraded Terns Pharmaceuticals (TERN) to Outperform following impressive Phase 1 CARDINAL trial results of TERN-701 in chronic myeloid leukemia, showing a 75% overall major molecular response rate and strong safety profile.
